Assay+ COVID-19 antigen rapid test is authorized with CE marker, the sensitivity is 90%, the specificity is 98.5%. Assay+ Covid 19 antigen rapid test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 from the nasopharyngeal swab from the suspected COVID-19 patients within five days of symptom onset. This test is an aid to differentiate Covid 19 virus infection from other respiratory tract infection caused by coronavirus 229E, NL63, OC43 and HKU1, or severe acute respiratory syndrome caused by SARS-CoV and MERS-CoV. The test should be performed in moderate, high or waived complexity tests. This test can also perform for the Point of Care (POC) purpose.